Rezolute Announces Pricing of Public Offering of $60 Million of Common Stock and Pre-Funded Warrants
Rezolute announced the pricing of a public offering worth $60 million, involving 11,250,000 common stock shares priced at $4.00 each and pre-funded warrants for 3,750,000 shares priced at $3.999 each. The offering is expected to close around June 17, 2024, pending customary conditions. Jefferies and Cantor are leading this offering, with BTIG, Craig-Hallum, H.C. Wainwright & Co., Jones and Maxim Group as co-managers. Gross proceeds are estimated at $60 million before any deductions. A shelf registration statement filed with the SEC on November 29, 2023, supports this offering. Rezolute is focused on developing treatments for hyperinsulinism.
- Rezolute has successfully priced a public offering worth $60 million.
- Gross proceeds from the offering are expected to be approximately $60 million.
- Jefferies and Cantor are acting as joint book-running managers.
- The offering includes both common stock and pre-funded warrants, providing flexibility to investors.
- Closing of the offering is expected soon, adding financial stability and enabling future endeavors.
- Rezolute focuses on developing transformative therapies for rare diseases, a potentially lucrative market.
- The offering will dilute current shareholders' equity.
- Gross proceeds are subject to deductions such as underwriting discounts and commissions.
- The closing is contingent on customary closing conditions, introducing potential uncertainties.
- The offering price of $4.00 per share may indicate lower market valuation.
- High involvement of various co-managers could imply elevated underwriting costs.
Insights
Rezolute's announcement of a $60 million public offering has several implications for investors. Firstly, the capital infusion can significantly bolster the company's financial health, essential for a late-stage biopharmaceutical firm involved in developing therapies for rare diseases. Such companies often face high research and development (R&D) costs and lengthy clinical trial processes. The $60 million raised could help Rezolute advance its pipeline, particularly the RZ358 antibody therapy for hyperinsulinism.
However, issuing new shares at
The concurrent offering of pre-funded warrants is a strategic move to attract investors who might prefer not to immediately affect the market price of the common stock. Pre-funded warrants are particularly favorable for institutional investors due to their minimal exercise price, thereby reducing the immediate cash outlay while still securing a future stake in the company.
Notably, the involvement of reputable underwriters like Jefferies and Cantor Fitzgerald adds credibility to the offering, suggesting strong institutional interest. This can often be a positive sign for retail investors, hinting at confidence in the company's future prospects.
Overall, while the dilution effect needs to be considered, the long-term benefits of enhanced financial stability and capability to advance clinical trials could outweigh the immediate concerns.
From a market perspective, Rezolute's focus on treating rare diseases, specifically hyperinsulinism, positions it in a niche yet potentially lucrative segment of the biopharmaceutical industry. Treatments for rare diseases often come with higher pricing power due to the lack of alternatives and the urgent need for effective solutions.
Rezolute's RZ358 therapy, which has shown promising results in clinical trials, represents a potentially game-changing product in its field. The market for hyperinsulinism treatments is relatively underserved, offering strong growth potential if the product successfully navigates through the final approval stages and commercialization.
The offering also indicates that Rezolute is gearing up for potentially expensive activities like large-scale clinical trials, regulatory filings and eventual commercialization. These steps are important for gaining market traction but are capital-intensive.
Furthermore, the timing of the offering just before a significant milestone like the anticipated closing on
For retail investors, the focus should be on the company's ability to effectively utilize these funds to reach its clinical and commercial milestones, which could drive significant value in the long term. However, attention should be paid to market reception and the stock's performance post-offering, as immediate market reactions might be volatile.
NEW YORK, June 13, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company committed to developing novel, transformative therapies for serious rare diseases, today announced the pricing of its previously announced underwritten public offering of an aggregate of 11,250,000 shares of its common stock at an offering price of
All shares of common stock and pre-funded warrants to be sold in the offering will be offered by Rezolute. The closing of the offering is expected to occur on or about June 17, 2024, subject to the satisfaction of customary closing conditions.
Jefferies and Cantor are acting as the joint book-running managers for the offering. BTIG, Craig-Hallum, H.C. Wainwright & Co., Jones and Maxim Group LLC are acting as co-managers for the offering.
A shelf registration statement on Form S-3 (File No. 333-275562) relating to the securities to be offered in the public offering was filed with the Securities and Exchange Commission (the “SEC”) and was declared effective on November 29, 2023. The public offering will be made only by means of a prospectus supplement and accompanying prospectus that form a part of the registration statement. A preliminary prospectus has been filed with the SEC and may be obtained on the SEC’s website at www.sec.gov. A final prospectus supplement and the accompanying prospectus relating to and describing the terms of the underwritten public offering will be filed with the SEC and, when available, may be obtained on the SEC’s website at www.sec.gov. Copies of the final prospectus supplement and accompanying prospectus relating to the public offering, when available, may be obtained by contacting: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, New York 10022, by telephone at 877-821-7388, or by email at prospectus_department@jefferies.com or Cantor Fitzgerald & Co., Attention: Capital Markets, 110 East 59th Street, 6th Floor, New York, New York 10022, or by email at prospectus@cantor.com
This press release does not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Rezolute, Inc.
Rezolute is a late-stage rare disease company focused on significantly improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (HI). The Company’s antibody therapy, RZ358, is designed to treat all forms of HI and has shown substantial benefit in clinical trials and real-world use for the treatment of congenital hyperinsulinism and tumor hyperinsulinism.
Forward-Looking Statements
Any statements in this press release about the Company’s future expectations, plans and prospects, including statements regarding the public offering, constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Forward-looking statements include any statements about the Company’s strategy, future operations and future expectations and plans and prospects for the Company, and any other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “goal,” “may,” “might,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions. Such forward-looking statements involve substantial risks and uncertainties that could cause the Company’s development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, those related to market and other financial conditions, the potential completion of the public offering, satisfaction of customary closing conditions related to the public offering and other factors discussed in the “Risk Factors” section contained in the preliminary prospectus supplement and the reports that the Company files with the SEC. Any forward-looking statements represent the Company’s views only as of the date of this press release. The Company anticipates that subsequent events and developments will cause its views to change. While the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so except as required by law.
Contacts:
Rezolute, Inc.
Christen Baglaneas
cbaglaneas@rezolutebio.com
508-272-6717
LHA Investor Relations
Tirth T. Patel
tpatel@lhai.com
212-201-6614
FAQ
What is the value of Rezolute's latest public offering?
When is the closing date for Rezolute's public offering?
At what price is Rezolute offering its common stock?
How many shares of common stock is Rezolute offering?
What are pre-funded warrants in Rezolute's public offering?
Who are the managers for Rezolute's public offering?
What is the ticker symbol for Rezolute?
